EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis

Jia Wang, Baolong Ding, Zhuying Jing, Yulu Zhu, Lihong Gao, Hongting Yao, Tiantian Tao, Xin Li iD

Therapeutic Advances in Medical Oncology · 2026-03 · 18

DOI: 10.1177/17588359261428081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 10.03.2026. Verfasst von Jia Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, Jiangsu 211166, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, jiangsu pharmaceutical association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COMPASSION-15 trial showed that cadonilimab plus chemotherapy has significant clinical advantages in patients with HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma compared to chemotherapy. This study evaluated the cost-effectiveness for patients in China and the United States.

Objective

To provide advice for patients on the use of cadonilimab.

Design

The cost-effectiveness analysis.

Methods

A partitioned survival model was conducted from perspective of the Chinese and U.S. healthcare systems over a lifetime horizon. Key parameters of the model were derived from COMPASSION-15 trial and published literature. In this study, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were taken as main outcomes. Sensitivity analyses, price simulations, and programmed death ligand 1 combined positive score (PD-L1 CPS) subgroup analyses were conducted to test robustness.

Results

In base-case analysis, cadonilimab plus chemotherapy group achieved an ICER of US dollars (USD) 32,630.84/QALY in China and USD 109,996.43/QALY in the United States, falling within the established willingness to pay (WTP) thresholds in both cases. At the current negotiated Chinese price (USD 208.94/100 mg), cadonilimab was cost-effective; in the United States, it remained cost-effective when priced below USD 437.87 (USD 100,000/QALY threshold) or USD 870.23 (USD 150,000/QALY threshold) per 100 mg. Subgroup analyses demonstrated that patients with PD-L1 CPS ⩾5 had 100% (China) and >94% (U.S.) probability of cost-effectiveness, whereas those with CPS

Schlagwörter

Stichwörter der Autor:innen

COMPASSION-15 trialcadonilimabcost-effectiveness analysisgastric cancerpartitioned survival model

Autor:innen und Institutionen

  • Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, Jiangsu 211166, People's Republic of China.
  • Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, People's Republic of China.
  • Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No. 101 Longmian Avenue, Jiangning District, Nanjing, Jiangsu 211166, People's Republic of China.
  • Department of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213100, People's Republic of China.

ORCID-Profile: Xin Li

Förderung

  • National Natural Science Foundation of China
  • jiangsu pharmaceutical association

Zitieren

APA

Wang, J., Ding, B., Jing, Z., Zhu, Y., Gao, L., Yao, H., Tao, T., & Li, X. (2026). Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261428081

Vancouver

Wang J, Ding B, Jing Z, Zhu Y, Gao L, Yao H, et al. Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261428081

BibTeX
@article{Wang2026,
  author = {Wang, Jia and Ding, Baolong and Jing, Zhuying and Zhu, Yulu and Gao, Lihong and Yao, Hongting and Tao, Tiantian and Li, Xin},
  title = {Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261428081}
}
Kostenlos starten →